FDA approves Abbott’s Bluetooth-connected pacemaker, defibrillator implants – FierceBiotech

Written by Conor Hale

Abbott has secured approvals from the FDA for its new generation of connected pacemakers and defibrillator implants.

The company’s Gallant line—including an implantable cardioverter defibrillator and a cardiac resynchronization therapy defibrillator—features Bluetooth technology, linking the devices with a personal smartphone app to help monitor patients with potentially life-threatening heart arrhythmias.

After pairing the device with Abbott’s myMerlinPulse software, patients and their clinicians can access data tracking the implants’ performance and event history. Care teams can also monitor patients remotely to identify episodes that may occur without any symptoms, the company said.

Read more here.

By Jessica Yap-Chung
Jessica Yap-Chung Profile Picture